ABAlexandre Beige

Alexandre Beige

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandre Beige has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • B. Bouillet

    Department of endocrinology and diabetology, centre hospitalier universitaire de Dijon, Dijon, France

    1 shared publication
  • Caroline Truntzer

    Translational Research Platform, Georges Francois Leclerc Cancer Center, Dijon, France

    1 shared publication
  • François Borsotti

    Department of Neurosurgery, University Hospital François Mitterrand, Dijon, France

    1 shared publication
  • François Ghiringhelli

    Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France

    1 shared publication
  • G. Truc

    Radiation therapy department, centre Georges-François-Leclerc, Dijon, France

    1 shared publication
  • Gilles Truc

    Department of Radiotherapy, Georges Francois Leclerc Cancer Center, Dijon, France

    1 shared publication

Latest Publications

  • Open Access

    Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study

    by Alexandre Beige, François Ghiringhelli, Julie Lecuelle, Caroline Truntzer, Gilles Truc, Julie Vincent, Walid Farah, François Borsotti, Irina Mazilu, Silvia Mihaela Ilie

    Background/Aim: Bevacizumab and chemotherapy are used in glioblastoma multiforme (GBM) relapse. However, the choice of chemotherapeutic agent remains an open question and this study aimed to evaluate the efficacy and safety of different combinations. Patients and Methods: Between June 2005 and August 2020, all patients treated with chemotherapy plus bevacizumab (BVZ) for recurrent glioblastoma in the Georges-François Leclerc Cancer Center, Dijon, France were included in this retrospective comparative study. The primary objective was progression-free survival (PFS) and as secondary objectives, overall survival (OS), disease control rate (DCR), and safety were investigated. Factors associated with response were also analyzed. Results: A total of 160 patients were screened: 100 received fotemustine plus BVZ (62%) and 62 (38%) received another cytotoxic agent plus BVZ: 35 (22%) irinotecan (IRI), 18 (11%) temozolomide (TEM), and 7 (4%) lomustine (LOM). In the whole population, median PFS was 4.47 months, median OS was 9 months, and 3-month DCR was 51%. Regarding survival according to treatment, median OS was significantly lower in the fotemustine group compared to that in other cytotoxic agents: 7.3 vs. 19.9 months. In the fotemustine group, steroids use at baseline and low Karnofsky performance status were associated with poor median OS. Grade 3-4 adverse events were found in 21.9%, with no difference between groups, but 7 patients had grade 5 adverse events in the fotemustine group. Conclusion: Using real-life data, this study showed lower efficacy of fotemustine and bevacizumab, as compared to IRI or TEM or LOM-BVZ combinations.